Cogent Biosciences Inc (COGT) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

•   Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025...

Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT...

Form 8-K - Current report

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50...

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Top-line results from registration-directed SUMMIT, PEAK and APEX trials expected in 2025 Phase 1 trial...

Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting

WALTHAM, Mass. and BOULDER, Colo., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT...

Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics

     Preclinical data highlight company’s fourth discovery stage program, a novel potent and selective KRAS(ON...

Form 8-K - Current report

Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis

413 patients enrolled in PEAK Phase 3 GIST trial, exceeding enrollment target; top-line results expected by end...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]